Clinical trials: Liver Diseases, Alcoholic
Nonalcoholic Fatty Liver Disease
Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis
Nonalcoholic fatty liver disease is one of the most common chronic liver diseases worldwide. Nonalcoholic steatohepatitis (NASH) is the active form of the disease which runs a progressive course and may result in liver cirrhosis…
- Trial name
- NCT01210989
- Testing
- Phyllanthus urinaria
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Cirrhosis, Portal Hypertension
Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
This is a multicenter, randomized, double-blind, placebo-controlled trial involving subjects with NASH cirrhosis and severe portal hypertension (defined as HVPG ≥12 mmHg as determined by the central reader assigned to this…
- Conditions
- Cirrhosis, Portal Hypertension, Non-alcoholic Steatohepatitis
- Trial name
- ENCORE-PH (NCT02960204)
- Testing
- Emricasan
- Where
- 37 sites in United States, Germany and 1 more
- Volunteers
- 263 people
- Sponsor
- Histogen
Diabetes Mellitus, Type 2, PreDiabetes
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
This 12-week controlled diet and weight intervention study seeks to define the molecular pathways that link excess body weight to the development of insulin resistance (IR).
- Conditions
- Diabetes Mellitus, Type 2, PreDiabetes, Insulin Resistance, Obesity
- Trial name
- NCT05165706
- Testing
- Dietary Intervention Mediterranean Low Carbohydrate Diet, Dietary Intervention Standard Low Carbohydrate Diet, Dietary Intervention Standard Low Fat Diet
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Stanford University
Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH)
Combined Active Treatment in Type 2 Diabetes With NASH
The aim of this multicentre, prospective, placebo-controlled, double-blind, randomized, 3-arm parallel group, interventional study is to assess for the first time the effects of either a combined therapy with the…
- Conditions
- Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)
- Trial name
- COMBAT_T2_NASH (NCT04639414)
- Testing
- Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector
- Where
- 26 sites in Austria, Germany
- Volunteers
- 192 people
- Sponsor
- German Diabetes Center
Non-Alcoholic Fatty Liver Disease, Liver Fat
Diet, Immunometabolism and Non-alcoholic Fatty Liver Disease
This study will assess the impact of 8-hour time restricted eating (8 hours of eating, 16 hours fasting) combined with a Mediterranean diet on metabolism and inflammation in adults with non-alcoholic fatty liver disease (NAFLD).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Liver Fat, Obesity, Inflammation
- Trial name
- NCT05968378
- Testing
- Standard healthy eating advice, eTRE plus Mediterranean diet
- Where
- Ireland
- Volunteers
- 60 people
- Sponsor
- University College Dublin
Non Alcoholic Steatohepatitis (NASH)
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
The primary objectives of this study are to evaluate the effect of Obeticholic Acid treatment compared to placebo on 1) histological improvement and 2) liver-related clinical outcomes in patients with non-cirrhotic nonalcoholic…
- Trial name
- REGENERATE (NCT02548351)
- Testing
- Obeticholic Acid
- Where
- 346 sites in United States, Australia and 19 more
- Volunteers
- 2,477 people
- Sponsor
- Intercept Pharmaceuticals
NAFLD - Nonalcoholic Fatty Liver Disease, NASH - Nonalcoholic Steatohepatitis
Effects of Exercise on VLDL-TG Metabolism
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from reversible hepatic steatosis to inflammation and fibrosis termed steatohepatitis (NASH) and cirrhosis.
- Trial name
- NCT03678727
- Where
- Denmark
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is a chronic, metabolic liver disease that is closely related to obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) in a bidirectional mode.
- Trial name
- OsteoNAFLD (NCT05493761)
- Testing
- Denosumab, Alendronate Sodium
- Where
- 3 sites in Greece
- Volunteers
- 72 people
- Sponsor
- Aristotle University Of Thessaloniki
Hepatic Disease
Ketotifen in Non-Alcoholic Fatty Liver Disease Patients
The aim of this study is to investigate the safety and efficacy of using ketotifen in patients with NAFLD patients without cirrhosis
- Trial name
- NCT05616442
- Testing
- Ketotifen, Vitamin E
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Chronic Kidney Diseases, NAFLD
Chronic Kidney Disease and Non-alcoholic Fatty Liver Diseases
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. This disease reportedly affects up to 30% of the general population in Western countries, especially in patients with…
- Trial name
- NAFLD (NCT04779905)
- Testing
- urinary albumbin/creatinine ratio
- Where
- Egypt
- Volunteers
- 62 people
- Sponsor
- Sohag University
Non-alcoholic Steatohepatitis (NASH)
A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects
This is a first-in-human (FIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of AZD4076 tetracosasodium in healthy male subjects at increasing single doses
- Trial name
- NCT02612662
- Testing
- AZD4076
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diagnoses Disease
Quantitative Ultrasound for Diagnosing Hepatic Steatosis in Nonalcoholic Fatty Liver Multicenter Study
To evaluate the diagnostic performance of quantitative ultrasound parameters for assessing hepatic steatosis in non-alcoholic fatty liver disease using histologic results as reference standard
- Trial name
- NCT04985188
- Testing
- Quantitative ultrasound (QUS) technique
- Volunteers
- 112 people
- Sponsor
- Seoul National University Hospital
Non-alcoholic Steatohepatitis (NASH)
Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
The purpose of this study was to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.
- Trial name
- TANDEM (NCT03517540)
- Testing
- Tropifexor (LJN452), Cenicriviroc (CVC)
- Where
- 65 sites in United States, Argentina and 15 more
- Volunteers
- 193 people
- Sponsor
- Novartis Pharmaceuticals
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Probiotics in the Treatment of NAFLD
Evaluate the effect of supplementation of probiotics on liver changes (histological and enzymatic), lipid profile and gut microbiota of patients with nonalcoholic steatohepatitis (NASH).
- Conditions
- Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver, Nonalcoholic, NAFLD
- Trial name
- NCT02764047
- Testing
- Probiotic
- Where
- Brazil
- Volunteers
- 58 people
- Sponsor
- Federal University of Health Science of Porto Alegre
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH
Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH, Non-Alcoholic Steato-Hepatitis (NASH)
- Trial name
- AGL13 (NCT06843148)
- Testing
- Niacin (250mg)
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Université de Sherbrooke
Alcoholic Liver Disease
Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease
Alcoholic liver disease represents the major health issues and it ranges from simple steatosis to cirrhosis. There is a paucity of data to support the allopathic intervention among these group of patients.
- Trial name
- NCT03503708
- Testing
- Livitol-70
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Composite Interceptive Med Science
Healthy
Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants
This is a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of multiple oral doses of PF-06835919 in healthy adult Japanese participants.
- Trial name
- NCT04427917
- Testing
- PF-06835919
- Where
- Belgium
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alcoholic Cirrhosis
Pangenomic Study During Alcoholic Cirrhosis
Hepatocellular carcinoma (HCC) is a frequent complication of cirrhosis. Occurrence of HCC could be linked with multiple functional region of genome.
- Trial name
- CDCHC (NCT01065233)
- Testing
- DNA extraction
- Where
- 4 sites in France
- Volunteers
- 1,325 people
- Sponsor
- Nantes University Hospital
Non-alcoholic Fatty Liver, Atherogenic Dyslipidemia
Genetic Pathways Leading to Fatty Liver and Atherogenic Dyslipidemia
The aims of the study are: 1. To investigate if carriers of apolipoprotein (apo) CIII loss-of-function (LOF) mutations produce less apo-CIII that results in reduction of large very low-density lipoprotein (VLDL) particle…
- Conditions
- Non-alcoholic Fatty Liver, Atherogenic Dyslipidemia, Insulin Resistance
- Trial name
- VARKIN (NCT04209816)
- Testing
- Lipoprotein kinetics
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 100 people
- Sponsor
- Marja-Riitta Taskinen
Hepatitis
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment…
- Trial name
- NCT07428538
- Testing
- Larsucosterol
- Where
- 92 sites in United States
- Volunteers
- 350 people
- Sponsor
- Bausch Health Americas, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.